Arrowhead Can't Ditch Investor Suit Over Hep B Drug Trial
A California judge on Tuesday tentatively refused to dismiss a putative shareholder class action against Arrowhead Research Corp. over claims that the biopharmaceuticals maker misled investors about the progress of human...To view the full article, register now.
Already a subscriber? Click here to view full article